Lisbiderm
Lisbiderm
Lisbiderm has been designed for the treatment of the atopic dermatitis.
Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin (dermatitis).
The skin becomes itchy, red, swollen,and cracked, even a clear fluid may come from the affected areas. It typically starts in childhood, with changing severity over the years. In children under one year of age, much of the body may be affected. In adults, the hands and feet are most commonly affected.
Scratching the affected areas worsens the symptoms, and those affected have an increased risk of skin infections due to the poor skin condition.
Many people with atopic dermatitis develop hay fever or asthma which are diseases related to a malfunctioning of the immune system.
In Lisbiotics we hypothesised that this illness was due to a skin and gut dysbiosis (unbalanced microbiome) that affects the skin condition and the correct response from the Inmunitary System and therefore producing the skin symptoms in a first step and finally appearing the respiratory problems.
Lisbiderm contains Lactobacillus rhamnosus that treats the AD specially in kids.
Lisbiderm also prevent the apparition of this illness specially in babies born by caesarean birth, since the kids have not been in contact with the microorganisms in the birth canal, which is so necessary for the proper development of the microbiota itself.
We decided to use this bacteria after studying several clinical trials worldwide some of them appear in the reference area.
Our technicians made a formula that will contain the strains mentioned protected so it will not be attacked by the gastric acids and will also resist alive several months in the capsules maintaining its activity.
References
- Wu YJ, Wu WF, Hung CW, Ku MS, Liao PF, Sun HL, Lu KH, Sheu JN, Lue KH. Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4-48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study. J Microbiol Immunol Infect. 2017 Oct;50(5):684-692. doi: 10.1016/j.jmii.2015.10.003. Epub 2015 Nov 27. PMID: 26733351.
- Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):223-7. doi: 10.1097/00005176-200302000-00012. PMID: 12548058.